Tuberculosis (TB) vaccines now in clinical trials are designed as prophylactic vaccines based on early-expressed antigens and are not geared toward preventing reactivation of an established latent infection. To tackle this problem, researchers at the Statens Serum Institut in Copenhagen, Denmark, and colleagues tested an experimental TB vaccine in mice aimed at offering protection both before and after exposure to Mycobacterium tuberculosis (Aagaard C et al. Nat Med. 2011;17:189-194).
Hampton T. Tuberculosis Protection. JAMA. 2011;305(9):876. doi:10.1001/jama.2011.216